SVB Leerink Upgrades Pacira Pharmaceuticals (PCRX) to Outperform
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $23.30 +1.30%
Rating Summary:
12 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 20 | New: 20
Rating Summary:
12 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 20 | New: 20
Join SI Premium – FREE
SVB Leerink analyst Ami Fadia upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Market Perform to Outperform with a price target of $44.00 (from $46.00).
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $32.52 yesterday.
You May Also Be Interested In
- Truist Securities Reinstates Pacira Pharmaceuticals (PCRX) at Buy
- Ashok Leyland Ltd. (AL:IN) PT Raised to INR194 at Nomura/Instinet
- Samsonite International SA (1910:HK) (SMSEY) PT Lowered to HK$19.60 at Macquarie
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
